50/120
2.1 / 5 stars
All 120 Win/Lose results shown below
BIIB Roast Me summary
BIOGEN INC. (BIIB). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinBIIB / S&P 17.85% / 15.20% |
LoseBIIB / S&P BIIB unavailable / 15.00% |
LoseBIIB / S&P BIIB unavailable / 50.40% |
| 2026-Q11/3 |
WinBIIB / S&P 4.17% / -4.33% |
LoseBIIB / S&P 1.23% / 11.30% |
LoseBIIB / S&P -8.19% / 27.70% |
| 2025-Q41/3 |
WinBIIB / S&P 25.64% / 2.65% |
LoseBIIB / S&P 2.22% / 9.00% |
LoseBIIB / S&P -21.38% / 13.40% |
| 2025-Q32/3 |
WinBIIB / S&P 11.54% / 8.12% |
WinBIIB / S&P 4.77% / 4.61% |
LoseBIIB / S&P -0.90% / 13.45% |
| 2025-Q21/3 |
LoseBIIB / S&P -8.22% / 10.94% |
LoseBIIB / S&P 3.36% / 4.83% |
WinBIIB / S&P 31.74% / 10.63% |
| 2025-Q11/3 |
LoseBIIB / S&P -10.52% / -4.27% |
LoseBIIB / S&P 1.59% / 4.98% |
WinBIIB / S&P 26.47% / 10.57% |
| 2024-Q41/3 |
LoseBIIB / S&P -21.11% / 2.41% |
LoseBIIB / S&P -1.62% / 5.25% |
WinBIIB / S&P 40.28% / 6.15% |
| 2024-Q31/3 |
LoseBIIB / S&P -16.38% / 5.89% |
LoseBIIB / S&P -3.86% / 5.89% |
WinBIIB / S&P 9.93% / 6.11% |
| 2024-Q21/3 |
WinBIIB / S&P 7.51% / 4.28% |
LoseBIIB / S&P -3.00% / 5.38% |
LoseBIIB / S&P -56.80% / 5.12% |
| 2024-Q10/3 |
LoseBIIB / S&P -16.67% / 10.56% |
LoseBIIB / S&P -4.37% / 5.71% |
LoseBIIB / S&P -62.83% / 5.59% |
| 2023-Q40/3 |
LoseBIIB / S&P 0.68% / 11.69% |
LoseBIIB / S&P -3.32% / 6.81% |
LoseBIIB / S&P -61.81% / 7.78% |
| 2023-Q30/3 |
LoseBIIB / S&P -9.77% / -3.27% |
LoseBIIB / S&P -3.57% / 7.52% |
LoseBIIB / S&P -48.73% / -5.03% |
| 2023-Q21/3 |
LoseBIIB / S&P 2.45% / 8.74% |
LoseBIIB / S&P -6.23% / 9.50% |
WinBIIB / S&P 31.10% / -8.57% |
| 2023-Q11/3 |
LoseBIIB / S&P 0.40% / 7.50% |
LoseBIIB / S&P -6.61% / 10.77% |
WinBIIB / S&P 120.57% / -15.69% |
| 2022-Q41/3 |
LoseBIIB / S&P 3.72% / 7.56% |
LoseBIIB / S&P -7.36% / 11.88% |
WinBIIB / S&P 100.67% / -17.99% |
| 2022-Q32/3 |
WinBIIB / S&P 30.92% / -4.88% |
LoseBIIB / S&P -6.64% / 13.47% |
WinBIIB / S&P 87.94% / -1.41% |
| 2022-Q21/3 |
WinBIIB / S&P -3.16% / -16.10% |
LoseBIIB / S&P -9.10% / 13.71% |
LoseBIIB / S&P 10.48% / 11.04% |
| 2022-Q10/3 |
LoseBIIB / S&P -12.22% / -4.60% |
LoseBIIB / S&P -14.16% / 15.97% |
LoseBIIB / S&P -49.35% / 42.23% |
| 2021-Q40/3 |
LoseBIIB / S&P -15.22% / 11.03% |
LoseBIIB / S&P -18.32% / 15.00% |
LoseBIIB / S&P -58.06% / 96.40% |
| 2021-Q30/3 |
LoseBIIB / S&P -18.27% / 0.58% |
LoseBIIB / S&P -22.17% / 10.77% |
LoseBIIB / S&P -65.40% / 69.42% |
| 2021-Q21/3 |
WinBIIB / S&P 23.78% / 8.55% |
LoseBIIB / S&P -19.26% / 6.58% |
LoseBIIB / S&P -62.82% / 51.81% |
| 2021-Q11/3 |
WinBIIB / S&P 14.25% / 6.17% |
LoseBIIB / S&P -12.61% / -1.06% |
LoseBIIB / S&P -40.44% / 7.39% |
| 2020-Q41/3 |
LoseBIIB / S&P -13.68% / 12.15% |
LoseBIIB / S&P -6.49% / -3.72% |
WinBIIB / S&P -21.07% / -33.42% |
| 2020-Q32/3 |
LoseBIIB / S&P 6.03% / 8.93% |
WinBIIB / S&P 0.21% / -2.04% |
WinBIIB / S&P 7.32% / -27.10% |
| 2020-Q22/3 |
LoseBIIB / S&P -15.43% / 20.54% |
WinBIIB / S&P 2.95% / -0.46% |
WinBIIB / S&P 26.88% / -27.11% |
| 2020-Q13/3 |
WinBIIB / S&P 6.62% / -19.60% |
WinBIIB / S&P 4.42% / 3.47% |
WinBIIB / S&P 39.43% / -14.75% |
| 2019-Q43/3 |
WinBIIB / S&P 27.45% / 9.07% |
WinBIIB / S&P 6.88% / 5.36% |
WinBIIB / S&P 45.60% / 2.99% |
| 2019-Q32/3 |
LoseBIIB / S&P -0.45% / 1.70% |
WinBIIB / S&P 7.55% / 5.02% |
WinBIIB / S&P 81.67% / 0.21% |
| 2019-Q22/3 |
LoseBIIB / S&P -1.06% / 4.30% |
WinBIIB / S&P 9.32% / 6.64% |
WinBIIB / S&P 90.38% / 8.65% |
| 2019-Q12/3 |
LoseBIIB / S&P -21.45% / 13.65% |
WinBIIB / S&P 9.67% / 8.12% |
WinBIIB / S&P 65.69% / 14.29% |
| 2018-Q42/3 |
LoseBIIB / S&P -14.83% / -13.52% |
WinBIIB / S&P 9.61% / 9.05% |
WinBIIB / S&P 81.04% / 18.23% |
| 2018-Q32/3 |
WinBIIB / S&P 21.73% / 7.71% |
WinBIIB / S&P 11.78% / 10.21% |
LoseBIIB / S&P -5.14% / 19.06% |
| 2018-Q22/3 |
WinBIIB / S&P 6.00% / 3.43% |
WinBIIB / S&P 9.86% / 9.03% |
LoseBIIB / S&P -7.34% / 14.46% |
| 2018-Q11/3 |
LoseBIIB / S&P -14.05% / -0.76% |
WinBIIB / S&P 9.21% / 7.68% |
LoseBIIB / S&P -12.21% / 12.46% |
| 2017-Q41/3 |
LoseBIIB / S&P 1.74% / 6.64% |
WinBIIB / S&P 7.21% / 7.03% |
LoseBIIB / S&P -29.59% / 13.82% |
| 2017-Q31/3 |
WinBIIB / S&P 15.39% / 4.48% |
LoseBIIB / S&P 3.70% / 5.68% |
LoseBIIB / S&P -7.74% / 17.57% |
| 2017-Q20/3 |
LoseBIIB / S&P -0.75% / 3.09% |
LoseBIIB / S&P 4.26% / 4.83% |
LoseBIIB / S&P -11.03% / 17.74% |
| 2017-Q11/3 |
LoseBIIB / S&P -3.58% / 6.07% |
WinBIIB / S&P 5.46% / 3.67% |
LoseBIIB / S&P -1.90% / 13.32% |
| 2016-Q42/3 |
LoseBIIB / S&P -9.41% / 3.82% |
WinBIIB / S&P 6.36% / 2.09% |
WinBIIB / S&P 10.37% / 7.05% |
| 2016-Q33/3 |
WinBIIB / S&P 29.45% / 3.85% |
WinBIIB / S&P 8.05% / 0.20% |
WinBIIB / S&P 15.69% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | BIIB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 65.36% | 20.78% |
| Annualized return | 65.36% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | BIIB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -35.36% | 83.14% |
| Annualized return | -8.36% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | BIIB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -28.56% | 319.30% |
| Annualized return | -3.31% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |